Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950134-07-005192
Filing Date
2007-03-08
Accepted
2007-03-08 16:58:46
Documents
8
Period of Report
2006-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K d43459e10vk.htm 10-K 1193279
2 PATENT AND TECHNOLOGY LICENSE AGREEMENT d43459exv10w59.htm EX-10.59 118990
3 AMENDMENT NO. 5 TO PATENT AND TECHNOLOGY LICENSE AGREEMENT d43459exv10w61.htm EX-10.61 12691
4 LIST OF SUBSIDIARIES d43459exv21w1.htm EX-21.1 2066
5 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM d43459exv23w1.htm EX-23.1 1688
6 CERTIFICATION OF CEO AND CFO PURSUANT TO RULE 13A-14(A) AND RULE 15D-14(A) d43459exv31w1.htm EX-31.1 16010
7 CERTIFICATION OF CEO AND CFO PURSUANT TO SECTION 906 d43459exv32w1.htm EX-32.1 5713
8 GRAPHIC d43459d4345901.gif GRAPHIC 5136
  Complete submission text file 0000950134-07-005192.txt   1359055
Mailing Address 301 CONGRESS AVE SUITE 1850 AUSTIN TX 78701
Business Address 301 CONGRESS AVE SUITE 1850 AUSTIN TX 78701 5127089310
INTROGEN THERAPEUTICS INC (Filer) CIK: 0001018710 (see all company filings)

EIN.: 742704230 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-21291 | Film No.: 07681543
SIC: 2834 Pharmaceutical Preparations